statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	873
SG - Singapore	213
CN - Cina	110
BR - Brasile	80
GB - Regno Unito	45
IT - Italia	41
HK - Hong Kong	40
DE - Germania	35
VN - Vietnam	31
UA - Ucraina	18
SE - Svezia	16
TR - Turchia	16
FI - Finlandia	13
CA - Canada	12
IN - India	11
PL - Polonia	9
ID - Indonesia	8
AR - Argentina	7
RU - Federazione Russa	7
MX - Messico	6
NL - Olanda	6
BE - Belgio	5
IR - Iran	5
ZA - Sudafrica	5
BD - Bangladesh	4
BO - Bolivia	3
ES - Italia	3
FR - Francia	3
IQ - Iraq	3
MA - Marocco	3
RS - Serbia	3
BG - Bulgaria	2
EC - Ecuador	2
JP - Giappone	2
KG - Kirghizistan	2
LT - Lituania	2
TW - Taiwan	2
AE - Emirati Arabi Uniti	1
AF - Afghanistan, Repubblica islamica di	1
AL - Albania	1
AO - Angola	1
AT - Austria	1
CL - Cile	1
CO - Colombia	1
DZ - Algeria	1
EG - Egitto	1
GI - Gibilterra	1
GR - Grecia	1
JO - Giordania	1
KE - Kenya	1
LK - Sri Lanka	1
LV - Lettonia	1
MY - Malesia	1
NI - Nicaragua	1
PH - Filippine	1
PY - Paraguay	1
QA - Qatar	1
SA - Arabia Saudita	1
SY - Repubblica araba siriana	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
VE - Venezuela	1
VG - Isole Vergini Britanniche	1
Totale	1.672

Nome	#
Applicability of laparoscopic approach to the resection of large adrenal tumours: a retrospective cohort study on 200 patients	255
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study	180
Spontaneous rupture of a hepatic epithelioid angiomyolipoma: damage control surgery. A case report	177
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors	170
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status	164
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest	149
Dosimetry for treatment with radiolabelled somatostatin analogues. A review	140
Financial aspects of sentinel lymph node biopsy in early breast cancer	136
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)	116
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients	112
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study	105
Totale	1.704

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	175	0	0	0	0	0	76	5	25	7	27	15	20
2021/2022	91	12	7	0	5	2	6	6	6	3	10	10	24
2022/2023	170	13	16	8	15	24	28	11	14	21	0	14	6
2023/2024	82	8	4	1	1	4	21	4	11	7	3	3	15
2024/2025	416	9	7	29	25	41	51	23	17	79	52	50	33
2025/2026	468	89	33	73	87	151	35	0	0	0	0	0	0
Totale													1.704

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara